Deferasirox
As of the edition of 20 October 2026, Deferasirox is a small molecule: marketed, first approved in 2005 (US); US protection ends in 2034.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2022
- Kind
- Small molecule
- Brand name
- Exjade
- First approved
- 2 November 2005 (US)
- Approvals on record
- 20 in 6 regions
- Holder of the most recent approval
- TEVA SANTE; 4 holders in all
- Registered trials
- 89, 17 stopped early
- Disease areas
- Blood and lymph; Nutrition and metabolism; Inherited and neonatal; Cancer; Heart and blood vessels; Immune system
US protection
US protection ends in 2034.
The last listed US drug-substance patent ends in 2034. The application that gives this date is held by Novartis.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product3 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 3 listings behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 10 | 7 | 0 | 0 |
| Phase 1 | 6 | 5 | 0 | 0 |
| Phase 2 | 44 | 27 | 2 | 12 |
| Phase 3 | 10 | 9 | 0 | 1 |
| Phase 4 | 19 | 15 | 0 | 4 |
| All trials | 89 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Novartis | Originator, Applicant and Lead sponsor of trials | 2002 to now |